Collegium Pharmaceutical(COLL)
$24.81+0.34 (+1.39%)
COLL
Collegium Pharmaceutical financials statements
$24.81
At close:+0.34 (+1.39%)
Want to see COLL full AI Analyst Report?
Collegium Pharmaceutical (COLL) Ratios
511 Followers
Collegium Pharmaceutical Ratios
COLL's free cash flow for Q3 2026 was $86.26M. For the 2026 fiscal year, COLL's free cash flow was decreased by $-277.00K and operating cash flow was $86.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 |
| Quick Ratio | 1.48 | 0.88 | 1.10 | 0.86 | 1.07 |
| Cash Ratio | 0.57 | 0.14 | 0.52 | 0.40 | 0.67 |
| Solvency Ratio | 0.21 | 0.17 | 0.21 | 0.12 | 0.29 |
| Operating Cash Flow Ratio | 0.75 | 0.40 | 0.60 | 0.29 | 0.37 |
| Short-Term Operating Cash Flow Coverage | 10.83 | 3.17 | 1.50 | 0.76 | 2.14 |
| Net Current Asset Value | $ -663.75M | $ -952.49M | $ -410.28M | $ -559.30M | $ -173.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.57 | 0.52 | 0.59 | 0.60 | 0.37 |
| Debt-to-Equity Ratio | 3.12 | 3.75 | 3.45 | 3.64 | 1.28 |
| Debt-to-Capital Ratio | 0.76 | 0.79 | 0.78 | 0.78 | 0.56 |
| Long-Term Debt-to-Capital Ratio | 0.75 | 0.77 | 0.71 | 0.73 | 0.50 |
| Financial Leverage Ratio | 5.49 | 7.27 | 5.85 | 6.03 | 3.41 |
| Debt Service Coverage Ratio | 3.29 | 2.25 | 1.05 | 0.78 | 2.33 |
| Interest Coverage Ratio | 2.27 | 2.30 | 2.00 | 0.53 | 0.84 |
| Debt to Market Cap | 0.64 | 0.92 | 0.64 | 0.89 | 0.38 |
| Interest Debt Per Share | 32.26 | 28.92 | 22.45 | 22.83 | 8.01 |
| Net Debt to EBITDA | 1.72 | 2.31 | 1.41 | 3.09 | 0.84 |
| Profitability Margins | |||||
| Gross Profit Margin | 59.35% | 59.76% | 57.55% | 45.15% | 54.40% |
| EBIT Margin | 22.41% | 27.32% | 28.07% | 7.41% | 6.37% |
| EBITDA Margin | 51.37% | 54.11% | 54.40% | 37.36% | 31.26% |
| Operating Profit Margin | 23.97% | 26.91% | 29.46% | 7.18% | 6.37% |
| Pretax Profit Margin | 11.87% | 15.61% | 13.36% | -6.22% | -1.22% |
| Net Profit Margin | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% |
| Continuous Operations Profit Margin | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% |
| Net Income Per EBT | 67.88% | 70.20% | 63.59% | 86.67% | -2119.65% |
| EBT Per EBIT | 49.51% | 58.02% | 45.36% | -86.58% | -19.14% |
| Return on Assets (ROA) | 3.79% | 4.16% | 4.21% | -2.13% | 10.33% |
| Return on Equity (ROE) | 20.84% | 30.23% | 24.64% | -12.83% | 35.24% |
| Return on Capital Employed (ROCE) | 15.38% | 14.72% | 24.36% | 4.50% | 4.27% |
| Return on Invested Capital (ROIC) | 10.18% | 9.78% | 12.21% | 3.19% | -80.93% |
| Return on Tangible Assets | 7.47% | 11.35% | 8.19% | -5.29% | 16.89% |
| Earnings Yield | 4.28% | 7.48% | 4.64% | -3.19% | 10.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.69 | 2.76 | 3.16 | 2.53 | 2.62 |
| Payables Turnover | 29.77 | 64.59 | 27.68 | 72.82 | 30.14 |
| Inventory Turnover | 7.76 | 7.15 | 7.44 | 5.47 | 7.26 |
| Fixed Asset Turnover | 48.18 | 31.34 | 25.75 | 17.59 | 10.20 |
| Asset Turnover | 0.47 | 0.38 | 0.50 | 0.40 | 0.40 |
| Working Capital Turnover Ratio | 6.97 | 24.09 | 17.19 | 41.72 | 7.44 |
| Cash Conversion Cycle | 133.62 | 177.53 | 151.48 | 205.76 | 177.71 |
| Days of Sales Outstanding | 98.82 | 132.10 | 115.61 | 144.07 | 139.54 |
| Days of Inventory Outstanding | 47.06 | 51.08 | 49.05 | 66.71 | 50.29 |
| Days of Payables Outstanding | 12.26 | 5.65 | 13.19 | 5.01 | 12.11 |
| Operating Cycle | 145.88 | 183.18 | 164.66 | 210.77 | 189.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 10.39 | 6.35 | 8.14 | 3.67 | 2.96 |
| Free Cash Flow Per Share | 10.33 | 6.30 | 8.13 | 3.62 | 2.91 |
| Dividend Paid and CapEx Coverage Ratio | 189.27 | 124.08 | 595.98 | 76.59 | 53.27 |
| Capital Expenditure Coverage Ratio | 189.27 | 124.08 | 595.98 | 76.59 | 53.27 |
| Operating Cash Flow Coverage Ratio | 0.35 | 0.24 | 0.41 | 0.18 | 0.40 |
| Operating Cash Flow to Sales Ratio | 0.42 | 0.32 | 0.48 | 0.27 | 0.37 |
| Free Cash Flow Yield | 22.31% | 21.99% | 26.41% | 15.62% | 15.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 23.38 | 13.39 | 21.57 | -31.39 | 9.13 |
| Price-to-Sales (P/S) Ratio | 1.88 | 1.46 | 1.83 | 1.69 | 2.36 |
| Price-to-Book (P/B) Ratio | 4.87 | 4.04 | 5.31 | 4.03 | 3.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.48 | 4.55 | 3.79 | 6.40 | 6.42 |
| Price-to-Operating Cash Flow Ratio | 4.46 | 4.51 | 3.78 | 6.32 | 6.30 |
| Price-to-Earnings Growth (PEG) Ratio | -3.13 | 0.40 | -0.07 | 0.23 | 0.06 |
| Enterprise Value Multiple | 5.38 | 5.01 | 4.78 | 7.62 | 8.38 |
| Enterprise Value | 2.16B | 1.71B | 1.47B | 1.32B | 724.94M |
| EV to EBITDA | 5.38 | 5.01 | 4.78 | 7.62 | 8.38 |
| EV to Sales | 2.76 | 2.71 | 2.60 | 2.85 | 2.62 |
| EV to Free Cash Flow | 6.59 | 8.43 | 5.37 | 10.77 | 7.13 |
| EV to Operating Cash Flow | 6.55 | 8.36 | 5.36 | 10.63 | 7.00 |
| Tangible Book Value Per Share | -16.20 | -25.56 | -10.67 | -14.97 | -1.88 |
| Shareholders’ Equity Per Share | 9.51 | 7.09 | 5.79 | 5.76 | 5.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.32 | 0.30 | 0.36 | 0.13 | 22.20 |
| Revenue Per Share | 24.62 | 19.57 | 16.80 | 13.71 | 7.92 |
| Net Income Per Share | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 |
| Tax Burden | 0.68 | 0.70 | 0.64 | 0.87 | -21.20 |
| Interest Burden | 0.53 | 0.57 | 0.48 | -0.84 | -0.19 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| SG&A to Revenue | 0.35 | 0.29 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.09 |
| Income Quality | 5.24 | 2.96 | 5.71 | -4.97 | 1.45 |
Currency in USD
